Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consistent weight loss versus exenatide's twice-daily profile.
Key findingDifferential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consist
What the researchers found
Differential pharmacology comparison of liraglutide and exenatide for T2DM: liraglutide's once-daily dosing, greater HbA1c reduction, and more consistent weight loss versus exenatide's twice-daily profile.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.
Therapeutics and clinical risk management, 6, 401-11
Citation
Pinkney, Jonathan; Fox, Thomas; Ranganath, Lakshminarayan. (2010). Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide.. Therapeutics and clinical risk management, 6, 401-11.